Moderate

Haemodialysis — adequacy and chronic complications

HD adequacy · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Maintenance haemodialysis requires adequate solute clearance (Kt/V), volume and symptom control, plus management of intradialytic complications and long-term sequelae. Adequacy targets and dry-weight assessment underpin good outcomes.

Red flags

  • Catheter-related bloodstream infection (fever, rigors on dialysis)
  • Severe intradialytic hypotension or arrhythmia
  • Access haemorrhage or thrombosis
  • Signs of under-dialysis: pericarditis, encephalopathy
  • Severe hyperkalaemia pre-dialysis with ECG changes

Assessment

Differential diagnosis

  • Inadequate dialysis (low Kt/V, access recirculation)
  • Intradialytic hypotension
  • Volume overload / under-dialysis
  • Access dysfunction
  • Anaemia/CKD-MBD contributing to symptoms
  • Uraemia from missed sessions

Investigations

  • Monthly urea reduction ratio and single-pool Kt/V (target spKt/V >=1.2 or URR >=65%)
  • Pre/post dialysis weights and interdialytic weight gain
  • U&E, calcium, phosphate, PTH, bicarbonate
  • Haemoglobin, ferritin, TSAT
  • Access surveillance (flow, pressures, recirculation)
  • Hepatitis B/C and vaccination status

Management

  • Prescribe dialysis dose to achieve spKt/V >=1.2 (thrice-weekly), adjusting time, blood/dialysate flow and dialyser
  • Assess and set dry weight clinically (and with bioimpedance/lung ultrasound where available) to control volume
  • Limit interdialytic weight gain with sodium/fluid restriction and dietary counselling
  • Manage intradialytic hypotension: reassess dry weight, cooler dialysate, slower ultrafiltration, avoid pre-dialysis antihypertensives/eating
  • Monitor and treat CKD-MBD, renal anaemia and metabolic acidosis per targets
  • Surveil vascular access and refer early for dysfunction/stenosis
  • Ensure infection prevention: minimise catheter use, hepatitis B vaccination, exit-site care
  • Review medications for dialysability and timing (give phosphate binders, hold hypotensives as needed)
  • Address cardiovascular risk and sudden-death risk (avoid large potassium/fluid shifts)
  • Provide dietary potassium/phosphate/fluid education
  • Assess for transplant candidacy and home dialysis options
  • Review adequacy, volume status and complications at regular multidisciplinary clinics

Drugs & doses

Erythropoiesis-stimulating agent (e.g. darbepoetin 0.45 micrograms/kg SC weekly) titrated to Hb 100-120 g/L
IV iron sucrose 200 mg per session as needed to maintain iron stores
Phosphate binder with meals (e.g. sevelamer 800-2400 mg PO TDS)
Cinacalcet 30-180 mg PO daily or etelcalcetide IV for secondary hyperparathyroidism
Alteplase 2 mg per lumen for catheter thrombosis (locking)
Midodrine 2.5-10 mg PO pre-dialysis for refractory intradialytic hypotension

Disposition

Maintenance haemodialysis unit with multidisciplinary follow-up. Admit for access infection, severe hypotension or under-dialysis complications. Transplant assessment where eligible.

Complications & pitfalls

  • Intradialytic hypotension and cardiovascular events
  • Access thrombosis/stenosis/infection
  • Dialysis-related amyloidosis
  • Malnutrition-inflammation complex
  • Catheter-related bloodstream infection
  • Sudden cardiac death

Exam pearls

  • Target spKt/V >=1.2; low adequacy predicts poor outcomes
  • Catheters carry the highest infection and mortality risk — favour fistulas
  • Treat intradialytic hypotension by reassessing dry weight, not just fluids
  • Minimise interdialytic weight gain to protect the heart
  • Longer/more frequent dialysis improves volume and phosphate control

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.